Pfizer (PFE) and BioNTech (BNTX) successfully invalidated two patents held by CureVac (CVAC) in a ruling by London's High Court on Tuesday.
The lawsuit, filed in September 2022, relates to messenger RNA technology used in their COVID-19 vaccine.
"The decision of the UK Court is an important one as we believe that these patents do not meet the requirements for patentability and should never have been granted," said a BioNTech spokesperson.
Pfizer and CureVac did not immediately respond to MT Newswires' request for comment.
Price: 29.32, Change: +0.12, Percent Change: +0.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments